Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Introduction Breast cancer (BC) with HER-2/neu overexpression or amplification (HER-2+) is
associated with a higher prevalence of brain metastases (BMs) when compared to other …

Background Herein, we report a complete response after whole brain radiotherapy (WBRT)
and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and …

Prognosis of patients with HER2+ breast-to-brain-metastasis (BBM) is dismal even after
current standard-of-care treatments, including surgical resection, whole-brain radiation, and …

Approximately 50% of patients with advanced human epidermal growth factor 2 (HER2)-
positive breast cancer and triple-negative breast cancer (TNBC) ultimately develop breast …

Epidemiological observations have shown that schizophrenia patients after long-term drug
treatment exhibited reduced tumor incidences. The potential anticancer effects of …

Simple Summary Thirty percent of patients with human epidermal growth factor receptor 2-
positive breast cancer and triple-negative breast cancer, and 15% of patients with the …

After the introduction of trastuzumab, a monoclonal antibody that binds to human epidermal
growth factor receptor 2 (HER2), the overall survival (OS) among patients with HER2 …

Background Distant metastasis (DM) from breast cancer has a poor prognosis. Our objective
was to develop and validate a nomogram to predict individual distant metastasis-free …

Purpose The benefit of whole brain radiotherapy (WBRT) for late stage breast cancer
patients with brain metastases has been questioned. In this study we evaluated survival and …